Pritelivir mesylate hydrate

Modify Date: 2024-01-15 17:52:23

Pritelivir mesylate hydrate Structure
Pritelivir mesylate hydrate structure
Common Name Pritelivir mesylate hydrate
CAS Number 1428321-10-1 Molecular Weight 516.61
Density N/A Boiling Point N/A
Molecular Formula C19H24N4O7S3 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of Pritelivir mesylate hydrate


Pritelivir mesylate hydrate (BAY 57-1293 mesylate hydrate), an inhibitor of the viral helicase-primase complex, exhibits antiviral activity in vitro and in animal models of herpes simplex virus (HSV) infection. Pritelivir mesylate hydrate is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) with the IC50 of 0.02 μM against HSV1-2[1].

 Names

Name Pritelivir mesylate hydrate

 Pritelivir mesylate hydrate Biological Activity

Description Pritelivir mesylate hydrate (BAY 57-1293 mesylate hydrate), an inhibitor of the viral helicase-primase complex, exhibits antiviral activity in vitro and in animal models of herpes simplex virus (HSV) infection. Pritelivir mesylate hydrate is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) with the IC50 of 0.02 μM against HSV1-2[1].
Related Catalog
Target

IC50: 0.02 μM (HSV1-2)[1]

In Vivo Pritelivir is the first in a class of antiviral agents that inhibit HSV replication by targeting the viral helicase–primase enzyme complex[2]. Pritelivir (0.03-45 mg/kg) significantly increases survival. Pritelivir (0.3-30 mg/kg) reduces mortality against HSV-1, E-377. Pritelivir has potent and resistance-breaking antiviral efficacy with potential for the treatment of potentially life-threatening HSV type 1 and 2 infections, including herpes simplex encephalitis[3]. Combination therapies of Pritelivir at 0.1 or 0.3 mg/kg/dose with Acyclovir (10 mg/kg/dose) are protective when compared to the vehicle treated group against HSV-2, strain MS[3]. Animal Model: Female BALB/c mice[3] Dosage: 0.03 to 45 mg/kg Administration: Administered orally, twice daily at approximately 12 h intervals, for 7 days Result: Survival was significantly increased to 80-100% as compared to the vehicle treatment. Even the lowest dose of 0.3 mg/kg was effective in increasing survival to 53%.
References

[1]. Ligat G, et al. Identification of Amino Acids Essential for Viral Replication in the HCMV Helicase-PrimaseComplex. Front Microbiol. 2018 Oct 23;9:2483.

[2]. Wald A, et al. Helicase-primase inhibitor Pritelivir for HSV-2 infection. N Engl J Med. 2014 Jan 16;370(3):201-10.

[3]. Quenelle DC, et al. Efficacy of pritelivir and acyclovir in the treatment of herpes simplex virus infections in a mouse model of herpes simplex encephalitis. Antiviral Res. 2018 Jan;149:1-6.

 Chemical & Physical Properties

Molecular Formula C19H24N4O7S3
Molecular Weight 516.61
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.